VNDA — Vanda Pharmaceuticals Inc. catalysts
Next verified catalyst
2026-09-01 — Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onycho · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Sev
Phase 2 · Onychomycosis of Toenail |
VNDA Vanda Pharmaceuticals Inc. | Trichostatin A |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to P
Phase 2 · Dry Eye |
VNDA Vanda Pharmaceuticals Inc. | VSJ-110 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan
Phase 2 · Hypertension, Uncontrolled Hypertension |
VNDA Vanda Pharmaceuticals Inc. | iloperidone |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|